Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Use of sapropterin dihydrochloride in maternal phenylketonuria. A European experience of eight cases.
[phenylketonuria]
Sapropterin
dihydrochloride
(
SD
)
is
the
first
drug
treatment
for
phenylketonuria
(
PKU
)
,
but
due
to
the
lack
of
data
,
its
use
in
maternal
PKU
must
be
undertaken
with
caution
as
noted
in
the
FDA
and
EMEA
labels
.
We
collected
data
from
eight
pregnancies
in
PKU
women
treated
with
SD
and
we
analysed
the
phenotypes
of
these
patients
,
their
tetrahydrobiopterin
(
BH
4
)
responsiveness
,
the
indications
for
SD
treatment
,
the
efficacy
(
metabolic
control
,
phenylalanine
(
Phe
)
tolerance
and
offspring
outcome
)
and
the
safety
data
.
Results
showed
that
in
the
seven
patients
known
to
be
responsive
to
BH
4
,
the
use
of
SD
during
pregnancy
was
efficient
in
terms
of
metabolic
control
and
Phe
tolerance
.
The
indications
for
giving
SD
included
the
failure
of
the
low
-
Phe
diet
(
n
 
=
 
3
)
,
the
fact
that
some
of
these
women
had
never
experienced
the
low
Phe
diet
(
n
 
=
 
2
)
,
one
unexpected
pregnancy
in
a
woman
currently
on
SD
and
one
pregnancy
where
the
foetus
was
known
to
have
PKU
.
The
offspring
of
these
seven
pregnancies
were
all
normal
babies
with
normal
birth
measurements
and
outcomes
.
No
side
effect
related
to
SD
was
observed
in
these
seven
cases
.
In
the
eighth
case
,
SD
was
prescribed
as
a
rescue
treatment
without
previous
knowledge
of
the
BH
4
responsiveness
to
a
woman
who
was
already
8
Â
weeks
pregnant
without
diet
.
The
birth
occurred
at
33
Â
weeks
of
gestational
age
with
Potter
syndrome
(
probably
related
to
the
absence
of
metabolic
control
during
the
first
trimester
)
and
the
baby
died
in
the
first
hours
of
life
.
In
conclusion
,
the
data
presented
here
provides
the
first
evidence
that
treatment
with
pharmacological
doses
of
SD
appears
to
be
efficient
and
safe
in
women
with
PKU
during
pregnancy
.
Its
use
should
,
however
,
be
restricted
to
those
women
previously
identified
to
be
clear
responders
to
BH
4
.
Diseases
Validation
Diseases presenting
"first evidence"
symptom
congenital adrenal hyperplasia
dentin dysplasia
esophageal adenocarcinoma
fabry disease
homocystinuria without methylmalonic aciduria
krabbe disease
liposarcoma
phenylketonuria
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom